FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Koné Kaniga

Research Profile

Chemicals & Drugs

Procedures

Microbial Sensitivity Tests

Physiology

Living Beings

Disorders

Concepts & Ideas

Drug Dose Response Relationship

Co-author Network

Publications

TOP 3
Dennis A K Rice; Koné Kaniga; Michael Lee; Rebecca Redman
Activity of doripenem versus comparators in subjects with baseline bacteraemia in six pooled phase 3 clinical trials.
Wendy He; Koné Kaniga; A Simon Lynch; Robert K Flamm; Todd A Davies
In vitro Etest synergy of doripenem with amikacin, colistin, and levofloxacin against Pseudomonas aeruginosa with defined carbapenem resistance mechanisms as determined by the Etest method.
Mahesh N Samtani; Robert Flamm; Koné Kaniga; Partha Nandy
Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Koné Kaniga (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Dennis A K Rice; Koné Kaniga; Michael Lee; Rebecca Redman
Activity of doripenem versus comparators in subjects with baseline bacteraemia in six pooled phase 3 clinical trials.
International journal of antimicrobial agents 2013;41(4):388-92.
2012: Wendy He; Koné Kaniga; A Simon Lynch; Robert K Flamm; Todd A Davies
In vitro Etest synergy of doripenem with amikacin, colistin, and levofloxacin against Pseudomonas aeruginosa with defined carbapenem resistance mechanisms as determined by the Etest method.
Diagnostic microbiology and infectious disease 2012;74(4):417-9.
2010: Mahesh N Samtani; Robert Flamm; Koné Kaniga; Partha Nandy
Pharmacokinetic-pharmacodynamic-model-guided doripenem dosing in critically ill patients.
Antimicrobial agents and chemotherapy 2010;54(6):2360-4.
2010: Koné Kaniga; Robert Flamm; Shin-Yir Tong; Michael Lee; Ian Friedland; Rebecca Redman
Worldwide experience with the use of doripenem against extended-spectrum-beta-lactamase-producing and ciprofloxacin-resistant Enterobacteriaceae: analysis of six phase 3 clinical studies.
Antimicrobial agents and chemotherapy 2010;54(5):2119-24.
2009: Stephen G Jenkins; Alan C Fisher; Janet A Peterson; SC Nicholson; Koné Kaniga
Meta-analysis of doripenem vs comparators in patients with pseudomonas infections enrolled in four phase III efficacy and safety clinical trials.
Current medical research and opinion 2009;25(12):3029-36.
2008: Daniel D Long; James B Aggen; Jason Chinn; Seok Ki Choi; Burton G Christensen; Paul R Fatheree; David Green; Sharath S Hegde; J Kevin Judice; Koné Kaniga; Kevin M Krause; Michael Leadbetter; Martin S Linsell; Daniel G Marquess; Edmund J Moran; Matthew B Nodwell; John L Pace; Sean G Trapp; S Derek Turner
Exploring the positional attachment of glycopeptide/beta-lactam heterodimers.
The Journal of antibiotics 2008;61(10):603-14.
2008: Daniel D Long; James B Aggen; Burton G Christensen; J Kevin Judice; Sharath S Hegde; Koné Kaniga; Kevin M Krause; Martin S Linsell; Edmund J Moran; John L Pace
A multivalent approach to drug discovery for novel antibiotics.
The Journal of antibiotics 2008;61(10):595-602.
2008: Alvaro Réa-Neto; Michael S Niederman; Suzana Margareth Lobo; Eric Schroeder; Michael Lee; Koné Kaniga; Nzeera Ketter; Philippe Prokocimer; Ian Friedland
Efficacy and safety of doripenem versus piperacillin/tazobactam in nosocomial pneumonia: a randomized, open-label, multicenter study.
Current medical research and opinion 2008;24(7):2113-26.
2008: Christopher Lucasti; Abel Jasovich; Obiamiwe Umeh; Joel Jiang; Koné Kaniga; Ian Friedland
Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study.
Clinical therapeutics 2008;30(5):868-83.
2008: Jean Chastre; Richard G Wunderink; Philippe Prokocimer; Michael Lee; Koné Kaniga; Ian Friedland
Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study.
Critical care medicine 2008;36(4):1089-96.
2007: Shazad Mushtaq; Marina Warner; Yigong Ge; Koné Kaniga; David M Livermore
In vitro activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes.
The Journal of antimicrobial chemotherapy 2007;60(2):300-11.
2005: Ronald Jones; Thomas R Fritsche; Yigong Ge; Koné Kaniga; Helio S Sader
Evaluation of PPI-0903M (T91825), a novel cephalosporin: bactericidal activity, effects of modifying in vitro testing parameters and optimization of disc diffusion tests.
The Journal of antimicrobial chemotherapy 2005;56(6):1047-52.
2005: Noe Reyes; Robert Skinner; Koné Kaniga; Kevin M Krause; Josephine Shelton; Glenmar P Obedencio; Alexander Gough; Michael Conner; Sharath S Hegde
Efficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus.
Antimicrobial agents and chemotherapy 2005;49(10):4344-6.
2005: Helio S Sader; Thomas R Fritsche; Koné Kaniga; Yigong Ge; Ronald Jones
Antimicrobial activity and spectrum of PPI-0903M (T-91825), a novel cephalosporin, tested against a worldwide collection of clinical strains.
Antimicrobial agents and chemotherapy 2005;49(8):3501-12.
2005: Yunhua Chen; Elizabeth Garber; Qiuqu Zhao; Yigong Ge; Matthew A Wikler; Koné Kaniga; Lisa Saiman
In vitro activity of doripenem (S-4661) against multidrug-resistant gram-negative bacilli isolated from patients with cystic fibrosis.
Antimicrobial agents and chemotherapy 2005;49(6):2510-1.
2005: Deborah L Higgins; Ray Chang; Dmitri V Debabov; Joey Leung; Terry Wu; Kevin M Krause; Erik Sandvik; Jeffrey M Hubbard; Koné Kaniga; Donald E Schmidt; Qiufeng Gao; Robert T Cass; Dane E Karr; Bret M Benton; Patrick P Humphrey
Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus.
Antimicrobial agents and chemotherapy 2005;49(3):1127-34.
2005: Jeng-Pyng Shaw; J Seroogy; Koné Kaniga; Deborah L Higgins; Michael M Kitt; Steven L Barriere
Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects.
Antimicrobial agents and chemotherapy 2005;49(1):195-201.
2004: Sharath S Hegde; Noe Reyes; Tania Wiens; Nicole Vanasse; Robert Skinner; Julia McCullough; Koné Kaniga; John L Pace; Roger Thomas; Jeng-Pyng Shaw; Glenmar P Obedencio; J Kevin Judice
Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria.
Antimicrobial agents and chemotherapy 2004;48(8):3043-50.
2004: Anna King; Ian Phillips; Koné Kaniga
Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentration-dependent anti-infective with multiple mechanisms of action against Gram-positive bacteria.
The Journal of antimicrobial chemotherapy 2004;53(5):797-803.
2003: John L Pace; Kevin Krause; Deborah Johnston; Dmitri Debabov; Terry Wu; Lesley Farrington; Cassie Lane; Deborah L Higgins; Burt Christensen; J Kevin Judice; Koné Kaniga
In vitro activity of TD-6424 against Staphylococcus aureus.
Antimicrobial agents and chemotherapy 2003;47(11):3602-4.